SUMMARY

Only two vaccines are routinely recommended during pregnancy – influenza vaccine is recommended throughout, and pertussis vaccine is recommended at 28–32 weeks but can be given later.

Some other vaccines can be administered in special circumstances but are not routinely recommended.

All live attenuated vaccines are contraindicated in pregnancy, although there has been no evidence of adverse effects from inadvertent administration.

Recommending vaccination to pregnant women is important as evidence shows they are more likely to get vaccinated if their healthcare provider advises it.

It is important for healthcare providers to discuss the benefits and the safety of vaccination during pregnancy. In particular, pointing out the benefits for the baby is important in helping women decide.

 

Introduction

Immunisation is increasingly becoming a routine part of antenatal care, but there remains some confusion among healthcare providers and patients about what to do. Recommendation by the healthcare provider has been shown to be the most significant factor in a pregnant woman’s decision to get vaccinated.1 It is important to be aware of the current recommendations and how best to communicate them to pregnant women.

All pregnancy vaccination recommendations can be found in the Australian Immunisation Handbook, in particular section 3.3.2 – Vaccination of women who are planning pregnancy, pregnant or breastfeeding, and preterm infants. The Handbook is regularly updated and healthcare professionals are encouraged to check for these updates.2

 

Recommendations for women planning pregnancy

The need for vaccination against hepatitis B, measles, mumps, rubella and varicella should be assessed as part of pre-conception care. When previous infection or vaccination history is uncertain, serology can be used to assess immunity to hepatitis B, measles, mumps and rubella. Serological testing for varicella is not reliable for assessing vaccine-induced immunity, although it can indicate previous natural infection.2

 

Recommendations for pregnant women

Current Australian guidelines recommend the seasonal influenza vaccine. When both tri- and quadrivalent vaccines are available, the quadrivalent vaccines (Fluarix Tetra or FluQuadri) are the preferred option, although the trivalent vaccines are all suitable if quadrivalent vaccines are not available (see section 4.7.4 of the Australian Immunisation Handbook).2 

The other recommended vaccine for pregnant women is the adult pertussis dTpa vaccine (Adacel or Boostrix). The safety of influenza and pertussis vaccines is very good, and they can be administered at the same consultation.3

Close household contacts and carers such as siblings, partners and grandparents should also be up to date with all of their age-appropriate immunisations, such as rotavirus, varicella and MMR (measles-mumps-rubella) and particularly pertussis vaccine. 

Influenza vaccination

The influenza vaccine should be administered with seasonal protection in mind so it protects pregnant women against strains circulating during the influenza season and protects babies likely to be born during that time. The vaccine is recommended during any trimester,4 although the greatest risk of adverse outcomes from influenza for the pregnant woman is in the third trimester. There are excellent data showing that vaccination in pregnancy also protects the infant in the first few months of life.5,6

As there are challenges in obtaining seasonal influenza vaccine during the summer months, the emphasis should be on administration of the vaccine as early as possible after the seasonal vaccine formulation becomes available in the next year. 

Pertussis vaccination

Pertussis infection is most severe in infants under the age of three months. Almost all deaths occur before six weeks of age which is the earliest the first vaccine dose can be given. High concentrations of maternal antibody, only achievable through vaccination during pregnancy and transmitted via the placenta to the baby, have been shown to give more than 90% protection against severe infection in the first three months of life.7,8

Although evidence on the optimal time for administration is rapidly evolving, current data support vaccination at 28–32 weeks gestation giving the highest infant antibody levels at birth (even in premature infants).9 This conveniently corresponds to the usual time when glucose tolerance tests are conducted. However, the only efficacy data – from experience in England with an emergency vaccination in pregnancy program – showed that there was still significant protection with vaccination as late as 14 days before birth.7 Based on recent advice from the Australian Technical Advisory Group on Immunisation,10 if the pertussis vaccine is given earlier than 28 weeks but still during pregnancy, it need not be repeated. 

 

Which vaccines can be given in special circumstances?

While not routinely recommended, some vaccines can be administered to at-risk women, on a case-by-case basis. For example, vaccines that can be given to pregnant women at high risk of exposure include pneumococcal polysaccharide vaccine and hepatitis B (see Table 3.3.1 in the Australian Immunisation Handbook).2 

 

Which vaccines are contraindicated?

Live attenuated viral and bacterial vaccines are contraindicated in pregnancy (see Box).2 In most cases, the risk is hypothetical. For example, limited safety data available from inadvertent administration of rubella and varicella vaccines are reassuring

Box - Contraindicated vaccines in pregnancy

 

BCG (Bacillus Calmette-Guérin) against tuberculosis

Oral typhoid

Japanese encephalitis (Imojev)

MMR (measles-mumps-rubella)

MMRV (measles-mumps-rubella-varicella)

Rotavirus

Varicella against chickenpox

Zoster against shingles


Source: Reference 2

 

How many pregnant women get vaccinated?

Vaccine uptake has significantly improved in Australia over the past few years. In 2012, it was estimated that one in four pregnant women were immunised against influenza.11 Uptake of influenza vaccine is thought to have more than doubled since then, with 60% of pregnant women immunised in 2015 (author’s unpublished data).

Following the recommendation for antenatal pertussis vaccine in 2015, early estimates indicate approximately 70% of mothers received a pertussis vaccine in the third trimester of their pregnancy. Much of this success is owed to GPs, as more than two-thirds of antenatal vaccines are given in general practice.

Women who are recommended vaccines by a health provider are more than 10 times as likely to be immunised compared to those who are not.12,13 Another important factor is easy access to vaccines – women are more willing to get vaccinated if it is available at the same time as an antenatal visit.11 

 

Communicating vaccination to pregnant women

Pregnant women report being bombarded with advice about what they should and should not do. There is evidence that unless it is recommended by their healthcare provider, vaccination is not a priority.14 Simply pointing out that it is recommended can often be enough for a pregnant woman to get vaccinated.

When recommending antenatal immunisation, it is important to remember that pregnant women trust their healthcare providers and are primarily interested in the health and well-being of their baby. More than 90% of pregnant women who are immunised report doing so to protect their baby,12 therefore framing the benefits of vaccination to focus on the baby is important. Evidence from clinical trials shows maternal vaccination protects young infants from disease.5,7,15 This knowledge is often the deciding factor for pregnant women to get vaccinated.

Unimmunised women often cite concerns about the safety of vaccination as a reason why they refused it during pregnancy.12 A number of studies have shown the safety of influenza and pertussis vaccines, and previous investigations in Australia have found that a similar proportion of pregnant women experience common adverse events as compared to non-pregnant women.16 Providers should discuss common, expected reactions with their patients and reassure them about the safety of the vaccine for the baby. There is a large body of evidence supporting the safety of antenatal vaccination for the fetus. It shows no increase in the risk of preterm labour, low birthweight, congenital malformation or fetal death.3,17 In fact, some studies have shown influenza vaccination during pregnancy is associated with a lower rate of stillbirth.18

 

Conclusion

Vaccination during pregnancy is an effective strategy for protecting mothers during a time when they are often more vulnerable to infections such as influenza. Antenatal vaccination can also protect infants in the first few months of life, before they receive their first course of childhood vaccines. While antenatal vaccination is improving in Australia, more women and their infants could be offered protection against disease if every healthcare provider recommended vaccination to their pregnant patients.

Conflict of interest: none declared

If you prescribe subscribe
 

References

  1. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, Leask J. Pregnant women\u2019s intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine while pregnant: a cross sectional survey. Vaccine 2013;31:3972-8.
  2. Department of Health. The Australian immunisation handbook 10th edition. Last updated 6 March 2017. [cited 2017 Jul 1]
  3. Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol 3015;126:1069-74.
  4. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Influenza vaccination during pregnancy (and in women planning pregnancy). Updated March 2017. [cited 2017 Jul 1]
  5. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64.
  6. Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, et al.; New Vaccine Surveillance Network. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 2011;204(Suppl 1):S141-8.
  7. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521-8.
  8. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012 2013. Clin Infect Dis 2015;60:333-7.
  9. Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Gonen R, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels \u2013 a prospective study. Vaccine 2014;32: 5787-93.
  10. Australian Technical Advisory Group on Immunisation. Australian Technical Advisory Group on Immunisation (ATAGI) 59th meeting, 18 and 19 February 2016 ATAGI Bulletin. Canberra: Australian Government Department of Health; 2016. [cited 2017 Jul 1]
  11. Wiley KE, Massey PD, Cooper SC, Wood NJ, Ho J, Quinn HE, et al. Uptake of influenza vaccine by pregnant women: a cross-sectional survey. Med J Aust 2013;198:373-5.
  12. Regan AK, Mak DB, Hauck YL, Gibbs R, Tracey L, Effler PV. Trends in seasonal influenza vaccine uptake during pregnancy in Western Australia: implications for midwives. Women Birth 2016;29:423-9.
  13. Mak DB, Regan AK, Joyce S, Gibbs R, Effler PV. Antenatal care provider\u2019s advice is the key determinant of influenza vaccination uptake in pregnant women. Aust N Z J Obstet Gynaecol 2015;55:131-7.
  14. Wiley KE, Cooper SC, Wood N, Leask J. Understanding pregnant women\u2019s attitudes and behavior toward influenza and pertussis vaccination. Qual Health Res 2015;25:360-70.
  15. Regan AK, de Klerk N, Moore HC, Omer SB, Shellam G, Effler PV. Effect of maternal influenza vaccination on hospitalization for respiratory infections in newborns: a retrospective cohort study. Pediatr Infect Dis J. 2016;35:1097-103.
  16. Regan AK, Tracey L, Blyth CC, Mak DB, Richmond PC, Shellam G, et al. A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women. BMC Pregnancy Childbirth 2015;15:61.
  17. Sheffield JS, Greer LG, Rogers VL, Roberts SW, Lytle H, McIntire DD, et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 2012;120:532-7.
  18. Regan AK, Moore HC, de Klerk N, Omer SB, Shellam G, Mak DB, et al. Seasonal trivalent influenza vaccination during pregnancy and the incidence of stillbirth: population-based retrospective cohort study. Clin Infect Dis 2016;62:1221-7.

Kerrie Wiley

Research fellow, School of Public Health, University of Sydney

Annette Regan

Epidemiological postdoctoral research fellow, Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia

Research fellow, School of Public Health, Curtin University, Western Australia

Peter McIntyre

Director, National Centre for Immunisation Research and Surveillance, The Children’s Hospital, Westmead, Sydney

Professor of Child and Adolescent Health, School of Public Health, University of Sydney

Senior staff specialist, The Children’s Hospital, Westmead, Sydney